Adrenergic Effect on Cytokine Release After Ex Vivo Healthy Volunteers’ Whole Blood LPS Stimulation

Inflammation

Volumn 39, Issue 3, 2016, Pages 1069-1075

  Papandreou, Vasiliki ^a   Kavrochorianou, Nadia ^a   Katsoulas, Theodoros ^a   Myrianthefs, Pavlos ^a   Venetsanou, Kyriaki ^a   Baltopoulos, George ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

dobutamine; inflammation; norepinephrine; sepsis

Indexed keywords

DOBUTAMINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METOPROLOL; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA; ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; TUMOR NECROSIS FACTOR;

ADRENERGIC ACTIVITY; ADULT; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; MALE; NORMAL HUMAN; SCANNING ELECTRON MICROSCOPY; BIOSYNTHESIS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SEPSIS;

ADRENERGIC AGENTS; BLOOD; CYTOKINES; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; NOREPINEPHRINE; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962193484     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-016-0338-y     Document Type: Article

References (38)

1. Riedemann, Niels C., Ren Feng Guo, and Peter A. Ward. 2003. The enigma of sepsis. Journal of Clinical Investigation 112: 460–467. doi:10.1172/JCI200319523.
2. Dellinger, R. Phillip, Mitchell M. Levy, Andrew Rhodes, Djillali Annane, Herwig Gerlach, Steven M. Opal, Jonathan E. Sevransky, et al. 2013. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical care medicine 41: 580–637. doi:10.1097/CCM.0b013e31827e83af.
3. van der Voort, P.H.J. 2006. The incomplete puzzle of vasoactive medication in (abdominal) sepsis. Critical care medicine 34: 1565–1566. doi:10.1097/01.CCM.0000216187.00379.12.
4. Lemaire, Lucienne C., Martijn D. de Kruif, Ida A. Giebelen, Marcel Levi, Tom van der Poll, and Michael Heesen. 2006. Dobutamine does not influence inflammatory pathways during human endotoxemia. Critical care medicine 34: 1365–1371. doi:10.1097/01.CCM.0000215514.96888.E3.
5. Guirao, X., A. Kumar, J. Katz, M. Smith, E. Lin, C. Keogh, S.E. Calvano, and S.F. Lowry. 1997. Catecholamines increase monocyte TNF receptors and inhibit TNF through beta 2-adrenoreceptor activation. The American journal of physiology 273: E1203–E1208.
6. Van der Poll, T., and S.F. Lowry. 1997. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. The American journal of physiology 273: R1885–R1890.
7. Severn, A., N.T. Rapson, C.A. Hunter, and F.Y. Liew. 1992. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. Journal of immunology (Baltimore, Md.: 1950) 148: 3441–3445.
8. Haskó, György, Csaba Szabó, Zoltán H. Németh, and Edwin A. Deitch. 2002. Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism. Journal of Neuroimmunology 122: 34–39.
9. Backer, De, Patrick Biston Daniel, Jacques Devriendt, Christian Madl, Didier Chochrad, Cesar Aldecoa, Alexandre Brasseur, Pierre Defrance, Philippe Gottignies, and Jean-Louis Vincent. 2010. Comparison of dopamine and norepinephrine in the treatment of shock. New England Journal of Medicine 362: 779–789. doi:10.1056/NEJMoa0907118.
10. Du, Yuming, Lirui Wang, Huijuan Shi, and Min Gao. 2015. Comparison of clinical effect of dopamine and norepinephrine in the treatment of septic shock. Pakistan journal of pharmaceutical sciences 28: 1461–1464.
11. Dinarello, C.A. 2000. Proinflammatory cytokines. Chest 118: 503–508.
12. Pinsky, Michael R. 2004. Dysregulation of the immune response in severe sepsis. The American journal of the medical sciences 328: 220–229.
13. van der Poll, T., S.E. Calvano, A. Kumar, S.M. Coyle, and S.F. Lowry. 1997. Epinephrine attenuates down-regulation of monocyte tumor necrosis factor receptors during human endotoxemia. Journal of leukocyte biology 61: 156–160.
14. Cavaillon, Jean-Marc, Minou Adib-Conquy, Catherine Fitting, Christophe Adrie, and Didier Payen. 2003. Cytokine cascade in sepsis. Scandinavian journal of infectious diseases 35: 535–544. doi:10.1080/00365540310015935.
15. Dinarello, C.A. 1997. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112: 321S–329S.
16. Papanicolaou, D.A., R.L. Wilder, S.C. Manolagas, and G.P. Chrousos. 1998. The pathophysiologic roles of interleukin-6 in human disease. Annals of internal medicine 128: 127–137.
17. Flierl, Michael A, Daniel Rittirsch, Markus Huber-Lang, J Vidya Sarma, and Peter A Ward. 2008. Catecholamines—crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora’s box? Molecular medicine (Cambridge, Mass.) 14: 195–204. doi:10.2119/2007-00105.
18. Marino, Franca, and Marco Cosentino. 2013. Adrenergic modulation of immune cells: an update. Amino Acids 45: 55–71. doi:10.1007/s00726-011-1186-6.
19. Myrianthefs, P., S. Karatzas, K. Venetsanou, E. Grouzi, P. Evagelopoulou, E. Boutzouka, G. Fildissis, I. Spiliotopoulou, and G. Baltopoulos. 2003. Seasonal variation in whole blood cytokine production after LPS stimulation in normal individuals. Cytokine 24: 286–292. doi:10.1016/j.cyto.2003.08.005.
20. Van der Poll, T., J. Jansen, E. Endert, H.P. Sauerwein, and S.J.H. Van Deventer. 1994. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infection and Immunity 62: 2046–2050.
21. Maes, Michael, Aihua Lin, Gunter Kenis, Belinda Egyed, and Eugene Bosmans. 2000. The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocytic products. Psychiatry Research 96: 245–253. doi:10.1016/S0165-1781(00)00216-X.
22. Röntgen, Philipp, Armin Sablotzki, Andreas Simm, Rolf Edgar Silber, and Elke Czeslick. 2004. Effect of catecholamines on intracellular cytokine synthesis in human monocytes. European Cytokine Network 15: 14–23.
23. Loop, Torsten, Bross Tobias, Humar Matjaz, Hoetzel Alexander, Schmidt Rene, Heike L. Pahl, Klaus K. Geiger, and Benedikt H.J. Pannen. 2004. Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. Anesthesia and analgesia 99: 1508–1515. doi:10.1213/01.ANE.0000132976.19021.1B.
24. Li, Chi-Yuan, Tsai Chien-Sung, Hsu Ping-Ching, Wu Ching-Tang, Wong Chih-Shung, and Ho Shung-Tai. 2003. Dobutamine modulates lipopolysaccharide-induced macrophage inflammatory protein-1alpha and interleukin-8 production in human monocytes. Anesthesia and analgesia 97: 210–215.
25. Bergmann, M., A. Gornikiewicz, T. Sautner, E. Waldmann, T. Weber, M. Mittlböck, E. Roth, and R. Függer. 1999. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock (Augusta, Ga.) 12: 421–427.
26. Hartemink, Koen J., and A.B. Johan Groeneveld. 2012. Vasopressors and inotropes in the treatment of human septic shock: effect on innate immunity? Inflammation 35: 206–213. doi:10.1007/s10753-011-9306-8.
27. Padro, Caroline J., and Virginia M. Sanders. 2014. Neuroendocrine regulation of inflammation. Seminars in Immunology 26. Elsevier Ltd: 357–368. doi:10.1016/j.smim.2014.01.003.
28. Ertel, W., J.P. Kremer, J. Kenney, U. Steckholzer, D. Jarrar, O. Trentz, and F.W. Schildberg. 1995. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85: 1341–1347.
29. Wiersinga, Willem Joost, Stije J. Leopold, Duncan R. Cranendonk, and Tom van der Poll. 2014. Host innate immune responses to sepsis. Virulence 5: 36–44. doi:10.4161/viru.25436.
30. de Montmollin, Etienne, Jerome Aboab, Arnaud Mansart, and Djillali Annane. 2009. Bench-to-bedside review: β-adrenergic modulation in sepsis. Critical Care 13: 230. doi:10.1186/cc8026.
31. Farmer, Pierre, and J. Pugin. 2000. Beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. American journal of physiology. Lung cellular and molecular physiology 279: L675–L682.
32. Suberville, S., A. Bellocq, B. Fouqueray, C. Philippe, O. Lantz, J. Perez, and L. Baud. 1996. Regulation of interleukin-10 production by beta-adrenergic agonists. European journal of immunology 26: 2601–2605. doi:10.1002/eji.1830261110.
33. Lawrence, Toby. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor perspectives in biology 1: a001651. doi:10.1101/cshperspect.a001651.
34. Parry, G.C., and N. Mackman. 1997. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. Journal of immunology (Baltimore, Md.: 1950) 159: 5450–5456.
35. Wen, A.Y., K.M. Sakamoto, and L.S. Miller. 2010. The role of the transcription factor CREB in immune function. The Journal of Immunology 185: 6413–6419. doi:10.4049/jimmunol.1001829.
36. Wu, Jeng-Yuan, Wen-Jinn Liaw, Chin Tzao, Shiu-Jen Chen, Jih-Hsin Wang, and Wu Chin-Chen. 2002. Comparison of terbutaline and dobutamine in rats with endotoxemia. The Chinese journal of physiology 45: 155–162.
37. Mayringer, I., M. Reindl, and T. Berger. 2000. A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells. Journal of immunological methods 235: 33–40.
38. Wadhwa, M., and R. Thorpe. 1998. Cytokine immunoassays: recommendations for standardisation, calibration and validation. Journal of immunological methods 219: 1–5.